134 related articles for article (PubMed ID: 34812040)
1. Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation.
Luo G; Lin X; Vega-Medina A; Xiao M; Li G; Wei H; Velázquez-Martínez CA; Xiang H
J Med Chem; 2021 Dec; 64(23):17098-17114. PubMed ID: 34812040
[TBL] [Abstract][Full Text] [Related]
2. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
3. VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1.
Wang X; Arceci A; Bird K; Mills CA; Choudhury R; Kernan JL; Zhou C; Bae-Jump V; Bowers A; Emanuele MJ
Mol Cell Biol; 2017 Jul; 37(13):. PubMed ID: 28416635
[TBL] [Abstract][Full Text] [Related]
4. RNF112-mediated FOXM1 ubiquitination suppresses the proliferation and invasion of gastric cancer.
Zhang S; Wang J; Hu W; He L; Tang Q; Li J; Jie M; Li X; Liu C; Ouyang Q; Yang S; Hu C
JCI Insight; 2023 Jun; 8(11):. PubMed ID: 37288663
[TBL] [Abstract][Full Text] [Related]
5. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3.
Zhang Z; Bu H; Yu J; Chen Y; Pei C; Yu L; Huang X; Tan G; Tan Y
Theranostics; 2019; 9(10):2882-2896. PubMed ID: 31244930
[TBL] [Abstract][Full Text] [Related]
6. Anaphase-promoting complex/cyclosome-CDH1-mediated proteolysis of the forkhead box M1 transcription factor is critical for regulated entry into S phase.
Park HJ; Costa RH; Lau LF; Tyner AL; Raychaudhuri P
Mol Cell Biol; 2008 Sep; 28(17):5162-71. PubMed ID: 18573889
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation-mediated degradation of FBXL2 stabilizes FOXM1 to induce cancer progression.
Ueda Y; Moriwaki K; Takeuchi T; Higuchi K; Asahi M
Biochem Biophys Res Commun; 2020 Jan; 521(3):632-638. PubMed ID: 31679690
[TBL] [Abstract][Full Text] [Related]
8. Development of a FOXM1-DBD Binding Assay for High-Throughput Screening Using TR-FRET Assay.
Lee MY; Haam CE; Mun J; Lim G; Lee BH; Oh KS
Biol Pharm Bull; 2021; 44(10):1484-1491. PubMed ID: 34602556
[TBL] [Abstract][Full Text] [Related]
9. A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression.
Bi Z; Liu W; Ding R; Wu Y; Dou R; Zhang W; Yuan X; Liu X; Xiong L; Guo Z; Mao C
Eur J Pharmacol; 2017 Feb; 796():175-189. PubMed ID: 28012972
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments.
Raghuwanshi S; Gartel AL
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189015. PubMed ID: 37913940
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
12. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
13. A structure-activity relationship study of Forkhead Domain Inhibitors (FDI): The importance of halogen binding interactions.
Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Tabatabaei Dakhili SY; Ussher JR; Velázquez-Martínez CA
Bioorg Chem; 2019 Dec; 93():103269. PubMed ID: 31654840
[TBL] [Abstract][Full Text] [Related]
14. A Cdh1-FoxM1-Apc axis controls muscle development and regeneration.
Chen Z; Li L; Xu S; Liu Z; Zhou C; Li Z; Liu Y; Wu W; Huang Y; Kuang M; Fan S; Li H; Li X; Song G; Wu WS; Chen J; Hou Y
Cell Death Dis; 2020 Mar; 11(3):180. PubMed ID: 32152291
[TBL] [Abstract][Full Text] [Related]
15. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
[TBL] [Abstract][Full Text] [Related]
16. A lignan induces lysosomal dependent degradation of FoxM1 protein to suppress β-catenin nuclear translocation.
Dong GZ; Jeong JH; Lee YI; Han YE; Shin JS; Kim YJ; Jeon R; Kim YH; Park TJ; Kim KI; Ryu JH
Sci Rep; 2017 Apr; 7():45951. PubMed ID: 28378765
[TBL] [Abstract][Full Text] [Related]
17. F-box protein FBXL2 inhibits gastric cancer proliferation by ubiquitin-mediated degradation of forkhead box M1.
Li LQ; Pan D; Chen H; Zhang L; Xie WJ
FEBS Lett; 2016 Feb; 590(4):445-52. PubMed ID: 26790640
[TBL] [Abstract][Full Text] [Related]
18. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1.
Zanin R; Pegoraro S; Ros G; Ciani Y; Piazza S; Bossi F; Bulla R; Zennaro C; Tonon F; Lazarevic D; Stupka E; Sgarra R; Manfioletti G
J Exp Clin Cancer Res; 2019 Jul; 38(1):313. PubMed ID: 31311575
[TBL] [Abstract][Full Text] [Related]
19. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
20. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.
Chen Y; Ruben EA; Rajadas J; Teng NNH
Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
